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The Activity of Heparin in the Presence and Absence of Caz* lons;
why the Anti-Xa Activity of LMW Heparins ls about two Times
Overestimated
Dear Sir.
The activi ty of a heparin preparation is most easi ly determined
relat ive to a heparin standard. I t  is also possible to express this
activi ty in an absolute way by indicating how much a given
concentrat ion of the heparin increases the velocit l ,  of thrombin or
factor Xa inactivation in plasma. This can be quanti tat ively
expressed as the increase of the reaction constant in the reaction:
Thrombin (factor Xa) + AT [[ l  * lnactive product
For reasons that are of l i t t le importance here, the reaction
constant, i .e. the decay constant of the enzyme in the plasma-
medium (k,1..) is expressed in min-r per pM of AT II I  in the
plasma (1). This constant t4..  is most easi ly visual ised as being
proportional to the inverse of the half-life time of the activated
clott ing factor in plasma. Heparin activi t ies can be unequivocal ly
defined in this way and do not need to be compared to a standard;
i t  is also independent of the method of comparison with the
standard.
lt is, however, not independent of the reaction conditions.
Because heparins, when administered to the^patient, exert their
anticoagulant action in the presence of Ca'*, it is natural to
compare heparin activities at physiological concentrations of
Ca ' - .
It has been found previously that the heparin dependent decay
of thrombin, induced by any type of heparin, is hardly dependent
on the Ca'* concentration (2). This is not true for factor Xa,
however, where Ca2+ ions produce a nearly twofold increase of
the activity of unfractionated heparin (UFH), whereas it has a
variable but considerably smaller effect on different low molecu-
lar weight heparins (2,3). tn this letter we should l ike to cal l
attention to the important consequences of these observations for
the comparison of the anti-factor Xa activity of a LMWH to that
of a UFH standard.
It is common practice to compare anti-factor Xa activities in
the absence of Ca'* ions, for the very reason that in the presence
of Ca:* ions special precautions have to be taken to prevent
disturbance of the measurement by activation of the clotting
system. ln vivo, however, the heparins act in the presence of
Ca2*, thus the activities measured in vitro in the presence of Ca2+
must be considered to have greater pharmacological relevance.
With regard to the inactivation of factor Xa (not of thrombin),
UFH is considerably suppressed in the absence of Car*, whereas
LMWH is not. This means that the anti-factor Xa activity of a
LMWH. when it is compared to a UFH standard in vitro without
Ca2* ions, is measured against a shrunken yardstick. Conse-
quently its anti-factor Xa activity is overestimated but not its anti-
thrombin activity. A spuriously high ratio of anti-factor Xa
activity over anti-thrombin activity results.
One might think that comparison of a LMWH to the LMWH
standard would remedy this situation. This is not true as long as
the declared activity of the LMWH standard itself is incorrect
because it has been determined by comparison to a UFH standard
in the absence of Ca2*. The comparison of a LMWH to the
LMWH standard may be correct and independent of the Ca2+
concentration, but the anti-factor Xa activity of the LMWH
standard itself has been obtained by calibration against the UFH
standard in the absence of Ca?+ ions, so that its declared activity is
overrated.
Table I Activities of UF-
and absencc of  Cal*  ions
and LMW hepar in standards in the prcscnce
ISH LMWHS
Act iv i ty  dcclared ( lU/mg)
ant i - thrombin
anti-iactor Xa
Absolute ant i - thrombin act iv i ty  (at  I  pg/ml) :
+ L a -
-  La-
Absolute anti-factor Xa activity (at I pg/ml):
+ Cal+
- ( -a-
Act iv i ty  in SIU/mg:
anti-thrombin
anti-factor Xa
193
193
6l
168
13.65 6 5-5
13.55  6 .50
4 25 2-01
I  88  1 .60
13650 6550
4250 2010
The absolute activitics are expressed in min '/pM AT III Each value is
obtained from minimally 12 determinations and the SEMs vary between
I  5  and  3%.
Abbreviations: ISH: 4th International Standard Heparin; LMWS: lst
lnternational Low Molecular Weight Heparin Standard, IU : Interna-
tional Unit (: USP Unit), SIU : Standard Independent Unit.
In order to estimate the precise magnitude of the overestima-
tion of the anti-factor Xa activity of LMWHs due to the Car+
effect, we accurately determined (SEM <3%) the absolute
activities of the International Heparin Standard (IHS) and of the
Low Molecular Weight Heparin Standard (11) in the presence
and absence of Ca2* ions (Table 1).
As with any other valid activity test, the results of the absolute
activity measurements can be used to compare the potency of the
preparation under study (i. e. the first international low molecular
weight standard [LMWS]) to the 4th international heparin
standard (IHS). The ratio of the absolute activity of the LMWHS
to that of the IHS is then multiplied by the IU content of the
standard (: 193 tU/mg). On the basis of the anti-factor Xa
activities in the absence of Ca2* of the two preparations (1.88 and
1.60 resp.) we calculate a specific anti-factor Xa activity of the
LMWS of 164 IU/mg (1.60/1.88 x 193 : 164). This is sufficiently
close to the 168 IU/mg stated by the manufacturers to conclude
that indeed the value on the label is obtained by comparing
activities in the absence of Ca2+. It also shows that the absolute
anti-factor Xa activity estimations reflect a proPerty that is
proportional to the anti-factor Xa tests used by the manufacturers
to establish the potency of the standard. We then calculated the
anti-factor Xa activity of the LMW standard on the basis of the
absolute anti-factor Xa activities in the presence of Ca2+. In this
case the activity of the LMWS was found to be 92 anfi.Xa IU per
mg (2.0114.25 x 193 : 92) instead of the 164 IU per ng found in
the absence of Caz+ . Evidently in the patient these heaarin$ act in
the presence of Caz+ so the 92 IU/mg is the more relevant figure.
The reportedly high anti-factor Xa activity of LMWH prepara-
tions must be attributed to at least two causes- One is the presence
of a certain amount of heparin molecules that, like pentasac-
charide, have anti-factor Xa activity but are too small to have
anti-thrombin activity below critical chainlength material
1  l ' 1
\"/r ieCLn , see e.g. [5]). The other is the laboratory artifact caused
by the Ca2+ effect discussed here. Due to the Ca-+ effect the anti-
factor Xa activity is overestimated to reach 168 IU/ml rather than
92 IU/ml. In our opinion these results show that comparison of
dif ferent types of heparin to the UFH standard in the absence of
Ca2* Ieads to confusion. We do not exclude the possibi l i ty that
there also exist heparin molecules with a high specif ic anti-
factor Xa activi tv and a low anti-thrombin activi ty but our results
shorv that such molecules are not the only. and not even the major
cause of increased anti- factor Xa activi ty in LMWHs.
A strong argument in favour of the use of a LMWH starldard
fol lows from these observations. Comparison of LMW heparins
among each other wil l  be largely independent of Ca'* effects. So
if an adequately cal ibrated LMWH standard ( i .  e in the present
case 92 IU anti  Xa/mg) is av_ailable, current methods that are
employed in the absence of Ca'* can for al l  practical purposes st i l l
be used to determine the activity of other LMWHs. This means
that, on basis of our present results, we recant our previous
opinion about the l imited usefulness of a LMWH standard (6).
Addit ional ly, i t  is worth our attention that 1 lnternational Unit
represents a roughly threefold higher absolute catalytic activity on
thrombin decay than on factor Xa decay (Table 1)' This fact
easily escapes attention if the anti-thrombin and the anti-factor
Xa activities of a standard preparation (UFH standard) by
definition are said to be equal. This is one of the reasons to
propose the use of the absolute activities for the quantisation of
heparin potency. Another reason is that this opens the possibility
to calculate the concentrations of active circulating heparins in
terms of Fg per ml plasma (5). We consequently defined a
standard independent unit of heparin activity (SIU) as.that
amount of heparin that raises the absolute activity by 1 min-' per
pM of AT III in the plasma (5). In Thble 1 we also give the
potency of the two standards in terms of SIU. From these data it
can be seen that 1,000 IUs of anti- thrombin activi ty represent 7.1
aIIa-SlU whereas 1,000 anti-factor Xa units represent2'2 aXa-
SIU. The shift from old to new units can be made by using these
ca lcu la t ion  coef f i c ien ts .
The fact that LMWHs should be compared to an UFH
standard in the presence of Ca2* is nevertheless independent of
the units in which heparin activities are expressed.
H.  C.  Hemker  and S.  Begu in
Department of Biochemistry, Cardiovascular Research Institute
Maistricht and Medicat Facultv Rijksuniversiteit Limburg, Maas-
tr icht, The Netherlands
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Considerations about the Gorrect Nomenclature
of Glycosaminoglycans (GAGs)
Dear Sir,
Recently you published a convient method for molecular mass
determination of heparin (1). We would l ike to support the
attempt from Dr. Nielsen to rename "low molecular weight
heparin" to "low molecular mass heparin". Therefore we would
like to focus on that problem and to propose to rename also the
other glycosaminoglycans according to their molecular mass and
their chemical structure. Mucopolysaccharides are endogenous
materials with widespread origins and biological effects. The most
important representatives of therapeutic use are heparins and
dermatansulfates. Heparin is an important anticoagulant drug and
has a molecular mass distribution between 3,000 and 30'Ofi) Dal-
ton (2). Several low molecular mass heparins (LMMH) have been
developed in order to avoid side reactions and to improve
bioavailability. Dermatansulfates have been successfully tested for
their anticoagulant potential. By depolymerisation of dermatan-
sulfates low molecular mass compounds have already been
gained.
These standard or unfractionated and low molecular mass
compounds are heterogeneous in their structure, degree of
sulfatation, and polymerisation and the distribution of the
molecular mass (3, 4). The term "glycosaminoglycan" was intro-
duced as a biochemical classification to indicate the chief common
characteristic of these and related compounds in the presence of
an aminosugar. Sequencing of these anionic polysaccharides i not
yet possible. But heparins, dermatansulfates and chondroitinsul-
fates have been cleaved to defined oligosaccharides by
heparinases or chondroitinases. Thus almost all disaccharide units
of the GAGs have been defined (5). The structure of 'major
disaccharide sequences of heparin was establishedfor example as
alpha-l,4-linked Liduronic acid 2-sulfals --+ glucoiamine N,6
disulfate (IdoA-2SO: + GIcNSO:-6SO3) (6).
The low molecular compounds are classified according to their
original substances. Individual structures have' not'been taken
into consideration to name the compounds. This may be justified
because even the original material is heterogeneous. ,Heparin,
heparan and hyaluronic acid consist of glucoSamine.a4d',wonic
acid. So they could be named polyglucosaminouronates
(Table 1). However, dermatansulfate and chondroitinsulfates A
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